AbbVie Strikes Tentative Deal In Testosterone MDL

By Lauraann Wood (September 10, 2018, 10:29 PM EDT) -- AbbVie Inc., the last remaining company to face claims that it failed to warn patients about the hidden dangers of testosterone replacement therapy products, has reached a tentative deal to exit the multidistrict litigation, according to a Monday filing in Illinois federal court.

U.S. District Judge Matthew Kennelly entered an order staying all pending cases against AbbVie as well as its subsidiaries Abbott Laboratories, Solvay Pharmaceuticals Inc. and Unimed Pharmaceuticals LLC in light of the companies agreeing to confidential terms in a global settlement of hundreds of plaintiffs' claims regarding their allegedly dangerous products.

Judge Kennelly's order also told the companies...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!